{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:48:55Z","timestamp":1793134135414,"version":"4.5.0"},"reference-count":35,"publisher":"American Association for Cancer Research (AACR)","issue":"12","license":[{"start":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:00:00Z","timestamp":1670371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"HHS | NIH | National Cancer Institute","award":["T32CA251070-01"],"award-info":[{"award-number":["T32CA251070-01"]}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,7]]},"abstract":"<jats:p>Ductal carcinoma in situ (DCIS) is a biologically heterogenous entity with uncertain risk for invasive ductal carcinoma (IDC) development. Standard treatment is surgical resection often followed by radiation. New approaches are needed to reduce overtreatment. This was an observational study that enrolled patients with DCIS who chose not to pursue surgical resection from 2002 to 2019 at a single academic medical center. All patients underwent breast MRI exams at 3- to 6-month intervals. Patients with hormone receptor\u2013positive disease received endocrine therapy. Surgical resection was strongly recommended if clinical or radiographic evidence of disease progression developed. A recursive partitioning (R-PART) algorithm incorporating breast MRI features and endocrine responsiveness was used retrospectively to stratify risk of IDC. A total of 71 patients were enrolled, 2 with bilateral DCIS (73 lesions). A total of 34 (46.6%) were premenopausal, 68 (93.2%) were hormone-receptor positive, and 60 (82.1%) were intermediate- or high-grade lesions. Mean follow-up time was 8.5 years. Over half (52.1%) remained on active surveillance without evidence of IDC with mean duration of 7.4 years. Twenty patients developed IDC, of which 6 were HER2 positive. DCIS and subsequent IDC had highly concordant tumor biology. Risk of IDC was characterized by MRI features after 6 months of endocrine therapy exposure; low-, intermediate-, and high-risk groups were identified with respective IDC rates of 8.7%, 20.0%, and 68.2%. Thus, active surveillance consisting of neoadjuvant endocrine therapy and serial breast MRI may be an effective tool to risk-stratify patients with DCIS and optimally select medical or surgical management.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>A retrospective analysis of 71 patients with DCIS who did not undergo upfront surgery demonstrated that breast MRI features after short-term exposure to endocrine therapy identify those at high (68.2%), intermediate (20.0%), and low risk (8.7%) of IDC. With 7.4 years mean follow-up, 52.1% of patients remain on active surveillance. A period of active surveillance offers the opportunity to risk-stratify DCIS lesions and guide decisions for operative management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-22-0263","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T11:38:12Z","timestamp":1669030692000},"page":"1579-1589","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Identifying Good Candidates for Active Surveillance of Ductal Carcinoma\n                    <i>In Situ<\/i>\n                    : Insights from a Large Neoadjuvant Endocrine Therapy Cohort"],"prefix":"10.1158","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3183-1056","authenticated-orcid":true,"given":"Alexa C.","family":"Glencer","sequence":"first","affiliation":[{"name":"1Department of Surgery, University of California San Francisco, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3938-3606","authenticated-orcid":true,"given":"Phoebe N.","family":"Miller","sequence":"additional","affiliation":[{"name":"2University of California San Francisco School of Medicine, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7664-3852","authenticated-orcid":true,"given":"Heather","family":"Greenwood","sequence":"additional","affiliation":[{"name":"3Department of Radiology, University of California San Francisco, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0096-9316","authenticated-orcid":true,"given":"Cristian K.","family":"Maldonado Rodas","sequence":"additional","affiliation":[{"name":"1Department of Surgery, University of California San Francisco, San Francisco, California."},{"name":"1Department of Surgery, University of California San Francisco, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5229-8687","authenticated-orcid":true,"given":"Rita","family":"Freimanis","sequence":"additional","affiliation":[{"name":"3Department of Radiology, University of California San Francisco, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5005-3803","authenticated-orcid":true,"given":"Amrita","family":"Basu","sequence":"additional","affiliation":[{"name":"1Department of Surgery, University of California San Francisco, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8079-7846","authenticated-orcid":true,"given":"Rita A.","family":"Mukhtar","sequence":"additional","affiliation":[{"name":"1Department of Surgery, University of California San Francisco, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3393-4857","authenticated-orcid":true,"given":"Case","family":"Brabham","sequence":"additional","affiliation":[{"name":"4Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9271-9431","authenticated-orcid":true,"given":"Paul","family":"Kim","sequence":"additional","affiliation":[{"name":"5Quinnipiac University School of Medicine, North Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8571-1148","authenticated-orcid":true,"given":"E. Shelley","family":"Hwang","sequence":"additional","affiliation":[{"name":"6Department of Surgery, Duke University, Durham, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1314-6976","authenticated-orcid":true,"given":"Jennifer M.","family":"Rosenbluth","sequence":"additional","affiliation":[{"name":"7Department of Medicine, University of California San Francisco, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4502-0035","authenticated-orcid":true,"given":"Gillian L.","family":"Hirst","sequence":"additional","affiliation":[{"name":"1Department of Surgery, University of California San Francisco, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Campbell","sequence":"additional","affiliation":[{"name":"1Department of Surgery, University of California San Francisco, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3117-9202","authenticated-orcid":true,"given":"Alexander D.","family":"Borowsky","sequence":"additional","affiliation":[{"name":"8Department of Pathology, University of California Davis, Sacramento, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9202-4568","authenticated-orcid":true,"given":"Laura J.","family":"Esserman","sequence":"additional","affiliation":[{"name":"1Department of Surgery, University of California San Francisco, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2022,12,7]]},"reference":[{"key":"2023032314122682500_","doi-asserted-by":"crossref","first-page":"e234","DOI":"10.1016\/S1470-2045(13)70598-9","article-title":"Addressing overdiagnosis and overtreatment in cancer: a prescription for change","volume":"15","author":"Esserman","year":"2014","journal-title":"Lancet Oncol"},{"key":"2023032314122682500_","doi-asserted-by":"crossref","first-page":"e2017124","DOI":"10.1001\/jamanetworkopen.2020.17124","article-title":"Association of a diagnosis of ductal carcinoma in situ with death from breast cancer","volume":"3","author":"Giannakeas","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2023032314122682500_","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/jnci\/djq099","article-title":"Overdiagnosis in cancer","volume":"102","author":"Welch","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"2023032314122682500_","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1001\/jama.2013.108415","article-title":"Overdiagnosis and overtreatment in cancer: an opportunity for improvement","volume":"310","author":"Esserman","year":"2013","journal-title":"JAMA"},{"key":"2023032314122682500_","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/cncr.20979","article-title":"Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study","volume":"103","author":"Collins","year":"2005","journal-title":"Cancer"},{"key":"2023032314122682500_","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1186\/s12885-015-1904-7","article-title":"Long-term outcomes of ductal carcinoma in situ of the breast: a systematic review, meta-analysis and meta-regression analysis","volume":"15","author":"Stuart","year":"2015","journal-title":"BMC Cancer"},{"key":"2023032314122682500_","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1146\/annurev-med-050715-104920","article-title":"Controversies in the treatment of ductal carcinoma in situ","volume":"68","author":"Barrio","year":"2017","journal-title":"Annu Rev Med"},{"key":"2023032314122682500_","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11912-019-0777-3","article-title":"Management of ductal carcinoma in situ (DCIS) of the breast: present approaches and future directions","volume":"21","author":"Solin","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"2023032314122682500_","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/jnci\/djr027","article-title":"Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS","volume":"103","author":"Wapnir","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"2023032314122682500_","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s10549-013-2813-6","article-title":"Eight-year update of a prospective study of wide excision alone for small low- or intermediate-grade ductal carcinoma in situ (DCIS)","volume":"143","author":"Wong","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"2023032314122682500_","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1470-2045(10)70266-7","article-title":"Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK\/ANZ DCIS trial","volume":"12","author":"Cuzick","year":"2011","journal-title":"Lancet Oncol"},{"key":"2023032314122682500_","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/jncimonographs\/lgq039","article-title":"Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast","volume":"2010","author":"Correa","year":"2010","journal-title":"J Natl Cancer Inst Monogr"},{"key":"2023032314122682500_","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1200\/JCO.2013.49.5077","article-title":"Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial","volume":"31","author":"Donker","year":"2013","journal-title":"J Clin Oncol"},{"key":"2023032314122682500_","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1200\/JCO.2014.56.2595","article-title":"Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS Trial","volume":"32","author":"W\u00e4rnberg","year":"2014","journal-title":"J Clin Oncol"},{"key":"2023032314122682500_","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1200\/JCO.18.00378","article-title":"Population-based assessment of the association between magnetic resonance imaging background parenchymal enhancement and future primary breast cancer risk","volume":"37","author":"Arasu","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4 Suppl","key":"2023032314122682500_","article-title":"Improved early stratification of invasive cancer risk using MRI in a ductal carcinoma in-situ short-term active surveillance cohort treated with neoadjuvant endocrine therapy [abstract]","volume":"80","author":"Kim","year":"2020"},{"key":"2023032314122682500_","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1200\/JCO.19.00510","article-title":"Phase II single-arm study of preoperative letrozole for estrogen receptor-positive postmenopausal ductal carcinoma in situ: CALGB 40903 (Alliance)","volume":"38","author":"Hwang","year":"2020","journal-title":"J Clin Oncol"},{"key":"2023032314122682500_","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2217\/fon-2018-0221","article-title":"Mammaprint\u2122: a comprehensive review","volume":"15","author":"Brand\u00e3o","year":"2019","journal-title":"Future Oncol"},{"key":"2023032314122682500_","doi-asserted-by":"crossref","first-page":"100756","DOI":"10.1016\/j.tranon.2020.100756","article-title":"Performance characteristics of the BluePrint\u00ae breast cancer diagnostic test","volume":"13","author":"Mittempergher","year":"2020","journal-title":"Transl Oncol"},{"key":"2023032314122682500_","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/0021-9681(84)90041-9","article-title":"Empiric comparison of multivariate analytic techniques: advantages and disadvantages of recursive partitioning analysis","volume":"37","author":"Cook","year":"1984","journal-title":"J Chronic Dis"},{"key":"2023032314122682500_","article-title":"ACR BI-RADS Atlas: Breast Imaging Reporting and Data System","author":"D'Orsi","year":"2013"},{"key":"2023032314122682500_","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/jamaoncol.2015.2607","article-title":"Rethinking the standard for ductal carcinoma in situ treatment","volume":"1","author":"Esserman","year":"2015","journal-title":"JAMA Oncol"},{"key":"2023032314122682500_","doi-asserted-by":"crossref","first-page":"649","DOI":"10.7326\/M15-0964","article-title":"Variability in pathologists' interpretations of individual breast biopsy slides: a population perspective","volume":"164","author":"Elmore","year":"2016","journal-title":"Ann Intern Med"},{"key":"2023032314122682500_","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/jama.2015.1405","article-title":"Diagnostic concordance among pathologists interpreting breast biopsy specimens","volume":"313","author":"Elmore","year":"2015","journal-title":"JAMA"},{"key":"2023032314122682500_","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1200\/JCO.18.01779","article-title":"Randomized placebo controlled trial of low-dose tamoxifen to prevent local and contralateral recurrence in breast intraepithelial neoplasia","volume":"37","author":"DeCensi","year":"2019","journal-title":"J Clin Oncol"},{"key":"2023032314122682500_","doi-asserted-by":"crossref","first-page":"e026797","DOI":"10.1136\/bmjopen-2018-026797","article-title":"The COMET (Comparison of operative versus monitoring and endocrine therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS)","volume":"9","author":"Hwang","year":"2019","journal-title":"BMJ Open"},{"key":"2023032314122682500_","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.ejca.2015.07.017","article-title":"Addressing overtreatment of screen detected DCIS; the LORIS trial","volume":"51","author":"Francis","year":"2015","journal-title":"Eur J Cancer"},{"key":"2023032314122682500_","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.ejca.2015.05.008","article-title":"Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study","volume":"51","author":"Elshof","year":"2015","journal-title":"Eur J Cancer"},{"key":"2023032314122682500_","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS603","article-title":"The international collaboration of active surveillance trials for low-risk DCIS (LORIS, LORD, COMET, LORETTA)","volume":"37","author":"Kanbayashi","year":"2019","journal-title":"J Clin Oncol"},{"key":"2023032314122682500_","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1200\/JCO.2008.18.3103","article-title":"Ductal carcinoma in situ: state of the science and roadmap to advance the field","volume":"27","author":"Kuerer","year":"2009","journal-title":"J Clin Oncol"},{"key":"2023032314122682500_","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cell.2017.12.007","article-title":"Multiclonal invasion in breast tumors identified by topographic single cell sequencing","volume":"172","author":"Casasent","year":"2018","journal-title":"Cell"},{"key":"2023032314122682500_","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jtbi.2004.08.002","article-title":"Evaluation of pathways for progression of heterogeneous breast tumors","volume":"232","author":"Sontag","year":"2005","journal-title":"J Theor Biol"},{"key":"2023032314122682500_","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/jamaoncol.2020.2535","article-title":"Association of event-free and distant recurrence-free survival with individual-level pathologic complete response in neoadjuvant treatment of stages 2 and 3 breast cancer: three-year follow-up analysis for the I-SPY2 adaptively randomized clinical trial","volume":"6","author":"Yee","year":"2020","journal-title":"JAMA Oncol"},{"key":"2023032314122682500_","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nrc2773","article-title":"Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis","volume":"10","author":"Reid","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"2023032314122682500_","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMms1914228","article-title":"Reconsidering prostate cancer mortality - the future of PSA screening","volume":"382","author":"Welch","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-22-0263\/3226346\/crc-22-0263.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/2\/12\/1579\/3285248\/crc-22-0263.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/2\/12\/1579\/3285248\/crc-22-0263.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T08:54:07Z","timestamp":1701420847000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/2\/12\/1579\/711471\/Identifying-Good-Candidates-for-Active"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,7]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12,7]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-22-0263","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.6551055.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545918.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545924","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6551055","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545918","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545924.v1","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,7]]}}}